Erasca (ERAS) Assets Average (2021 - 2026)
Erasca's (ERAS) quarterly Assets Average came in at $428.7 million in Q1 2026, down 11.95% YoY from $486.9 million in Q1 2025, and up 5.0% on a QoQ basis from $408.3 million in Q4 2025.
Erasca (ERAS) Assets Average (2021 - 2026) Analysis & Trends
Erasca (ERAS) has 6 years of Assets Average data on file, last reported at $428.7 million in Q1 2026.
- Quarterly Assets Average fell 11.95% year-over-year to $428.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $428.7 million (down 11.95% YoY) and the FY2025 annual result came in at $449.3 million, changed 0.1% from the prior year.
- Assets Average rose to $428.7 million in Q1 2026, from $408.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $527.3 million in Q3 2024 to a low of $382.7 million in Q1 2024.
- A 5-year average of $455.7 million and a median of $454.1 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average dropped 22.1% — and 2025, when it gained 27.24%.
- Tracing ERAS's Assets Average over 5 years: stood at $480.7 million in 2022, then retreated by 15.25% to $407.4 million in 2023, then gained by 26.6% to $515.7 million in 2024, then retreated by 20.83% to $408.3 million in 2025, then increased by 5.0% to $428.7 million in 2026.
- The last three Assets Average figures came in at $428.7 million (Q1 2026), $408.3 million (Q4 2025), and $432.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 448.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 448.14 Mn |
| Mar 31, 2026 | 428.69 Mn |
| Dec 31, 2025 | 408.28 Mn |
| Sep 30, 2025 | 432.89 Mn |
| Jun 30, 2025 | 458.32 Mn |
| Mar 31, 2025 | 486.89 Mn |
| Dec 31, 2024 | 515.71 Mn |
| Sep 30, 2024 | 527.32 Mn |
| Jun 30, 2024 | 447.88 Mn |
| Mar 31, 2024 | 382.66 Mn |
| Dec 31, 2023 | 407.35 Mn |
| Sep 30, 2023 | 430.03 Mn |
| Jun 30, 2023 | 454.10 Mn |
| Mar 31, 2023 | 491.23 Mn |
| Dec 31, 2022 | 480.67 Mn |
| Sep 30, 2022 | 445.63 Mn |
| Jun 30, 2022 | 460.15 Mn |
| Mar 31, 2022 | 488.44 Mn |
| Dec 31, 2021 | 511.68 Mn |
| Sep 30, 2021 | 366.17 Mn |